SIRT1/PGC1a-Dependent increase in oxidative phosphorylation supports chemotherapy resistance of colon cancer

Clinical Cancer Research

Volumn 21, Issue 12, 2015, Pages 2870-2879

  Vellinga, Thomas T ^a   De Boer, Vincent C J ^b   Fatrai, Szabolcs ^a   Van Schelven, Susanne ^a   Trumpi, Kari ^a   Verheem, Andre ^a   Snoeren, Nikol ^a   Emmink, Benjamin L ^a   Koster, Jan ^b   Rinkes, Inne H M Borel ^a   Kranenburg, Onno ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; MITOCHONDRIAL PROTEIN; OXALIPLATIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; SIRTUIN 1; ANTINEOPLASTIC AGENT; PPARGC1A PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

AEROBIC METABOLISM; ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOGENESIS; BIOMASS; CANCER RESISTANCE; COLON CANCER; CONTROLLED STUDY; DEACETYLATION; DISEASE FREE SURVIVAL; ELECTRON TRANSPORT; ENERGY METABOLISM; EPIGENETICS; GENE EXPRESSION PROFILING; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MALE; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; OVERALL SURVIVAL; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CLEAVAGE; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; TRANSCRIPTOMICS; TUMOR GROWTH; TUMOR VOLUME; UPREGULATION; COLONIC NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; LIVER TUMOR; METABOLISM; MITOCHONDRION; OXIDATION REDUCTION REACTION; PATHOLOGY; SECONDARY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ENERGY METABOLISM; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; LIVER NEOPLASMS; MITOCHONDRIA; OXIDATION-REDUCTION; OXIDATIVE PHOSPHORYLATION; SIRTUIN 1; TRANSCRIPTION FACTORS;

EID: 84941950274     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2290     Document Type: Article

References (47)

1. Lucas AS, O'Neil BH, Goldberg RM. A decade of advances in cytotoxic chemotherapy for metastatic colorectal cancer. Clin Colorectal Cancer 2011;10:238-44.
2. Longley DB, Allen WL, Johnston PG. Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Biochim Biophys Acta 2006;1766:184-96.
3. Crea F, Danesi R, Farrar WL. Cancer stem cell epigenetics and chemoresistance. Epigenomics 2009;1:63-79.
4. Melo DSE, Wang X, Jansen M, Fessler E, Trinh A, de Rooij LP, et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med 2013; 19:614-8.
5. Roepman P, Schlicker A, Tabernero J, Majewski I, Tian S, Moreno V, et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-To-mesenchymal transition. Int J Cancer 2014;134:552-62.
6. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 2013; 19:619-25.
7. Schlicker A, Beran G, Chresta CM, McWalter G, Pritchard A, Weston S, et al. Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Med Genomics 2012; 5:66.
8. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 2009;324:1029-33.
9. Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 1994;269:23757-63.
10. SemenzaGL.HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest 2013;123:3664-71.
11. Obre E, Rossignol R. Emerging concepts in bioenergetics and cancer research: Metabolic flexibility, coupling, symbiosis, switch, oxidative tumors, metabolic remodeling, signaling and bioenergetic therapy. Int J Biochem Cell Biol 2015;59C:167-81.
12. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
13. Jose C, Bellance N, Rossignol R. Choosing between glycolysis and oxidative phosphorylation: A tumor's dilemma? Biochim Biophys Acta 2011;1807: 552-61
14. Moreno-Sanchez R, Rodríguez-Enríquez S, Marín-Hernandez A, Saavedra E. Energy metabolism in tumor cells. FEBS J 2007;274:1393-418.
15. Butler EB, Zhao Y, Munoz-Pinedo C, Lu J, Tan M. Stalling the engine of resistance: Targeting cancer metabolism to overcome therapeutic resistance. Cancer Res 2013;73:2709-17.
16. Zhao Y, Butler EB, TanM. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 2013;4:e532.
17. Cao X, Fang L, Gibbs S, Huang Y, Dai Z, Wen P, et al. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemother Pharmacol 2007;59: 495-505.
18. Cufi S, Corominas-Faja B, Vazquez-Martin A, Oliveras-Ferraros C, Dorca J, Bosch-Barrera J, et al. Metformin-induced preferential killing of breast cancer initiating CD44φCD24/low cells is sufficient to overcome primary resistance to trastuzumab in HER2φhuman breast cancer xenografts. Oncotarget 2012;3:395-8.
19. Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF, et al. 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 2004;64:31-4.
20. Lu CW, Lin SC, Chien CW, Lin SC, Lee CT, Lin BW, et al. Overexpression of pyruvate dehydrogenase kinase 3 increases drug resistance and early recurrence in colon cancer. Am J Pathol 2011;179:1405-14.
21. Emmink BL, van Houdt WJ, Vries RG, Hoogwater FJ, Govaert KM, Verheem A, et al. Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan. Gastroenterology 2011;141: 269-78.
22. Snoeren N, van Hooff SR, Adam R, van Hillegersberg R, Voest EE, Guettier C, et al. Exploring gene expression signatures for predicting disease free survival after resection of colorectal cancer liver metastases. PLoS ONE 2012;7:e49442.
23. Maier T, Güell M, Serrano L. Correlation of mRNA and protein in complex biological samples. FEBS Lett 2009;583:3966-73.
24. Tian Q, Stepaniants SB, Mao M, Weng L, Feetham MC, Doyle MJ, et al. Integrated genomic and proteomic analyses of gene expression in Mammalian cells. Mol Cell Proteomics 2004;3:960-9.
25. Davis EJ, Davis-van Thienen WI. An assessment of the role of proton leaks in the mechanistic stoichiometry of oxidative phosphorylation. Arch Biochem Biophys 1991;289:184-6.
26. Birket MJ, Orr AL, Gerencser AA, Madden DT, Vitelli C, Swistowski A, et al. A reduction in ATP demand and mitochondrial activity with neural differentiation of human embryonic stem cells. J Cell Sci 2011;124:348-58.
27. Wang RH, Sengupta K, Li C, Kim HS, Cao L, Xiao C, et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 2008;14:312-23.
28. Knight JR, Milner J. SIRT1, metabolism and cancer. Curr Opin Oncol 2012;24:68-75.
29. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006;15: 1109-22.
30. Puigserver P. Tissue-specific regulation ofmetabolic pathways through the transcriptional coactivator PGC1-Alpha. Int. J Obes 2005;29:S5-9.
31. Weijl NI, Cleton FJ, Osanto S. Free radicals and antioxidants in chemotherapy-induced toxicity. Cancer Treat Rev 1997;23:209-40.
32. Zhou Y, Tozzi F, Chen J, Fan F, Xia L, Wang J , et al. Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells. Cancer Res 2012;72:304-14.
33. Shlomi T, Benyamini T, Gottlieb E, Sharan R, Ruppin E. Genome-scale metabolic modeling elucidates the role of proliferative adaptation in causing the Warburg effect. PLoS Comput Biol 2011;7:e1002018.
34. Oliva CR, Moellering DR, Gillespie GY, Griguer CE. Acquisition of chemoresistance in gliomas is associated with increased mitochondrial coupling and decreased ROS production. PLoS ONE 2011;6:e24665.
35. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
36. Osley MA, Tsukuda T, Nickoloff JA. ATP-dependent chromatin remodeling factors and DNA damage repair. Mutat Res 2007;618:65-80.
37. Deng CX. SIRT1, is it a tumor promoter or tumor suppressor? Int J Bio Sci 2009;5:147-52.
38. Chu F, Chou PM, Zheng X, Mirkin BL, Rebbaa A. Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1. Cancer Res 2005;65:10183-7.
39. Vazquez F, Lim JH, Chim H, Bhalla K, Girnun G, Pierce K, et al. PGC1alpha expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell 2013;23:287-301.
40. Lim JH, Luo C, Vazquez F, Puigserver P. Targeting mitochondrial oxidative metabolism in melanoma causes metabolic compensation through glucose and glutamine utilization. Cancer Res 2014;74:3535-45.
41. Antoniali G, Lirussi L, D'Ambrosio C, Dal Piaz F, Vascotto C, Casarano E, et al. SIRT1 gene expression upon genotoxic damage is regulated by APE1 through nCaRE-promoter elements. Mol Biol Cell 2014;25:532-47.
42. Canto C, Auwerx J. Targeting sirtuin 1 to improvemetabolism: All you need is NAD(φ)? Pharmacol Rev 2012;64:166-87.
43. Canto C, Auwerx J. Caloric restriction, SIRT1 and longevity. Trends Endocrinol Metab 2009;20:325-31.
44. Martin SG, Laroche T, Suka N, Grunstein M, Gasser SM. Relocalization of telomeric Ku and SIR proteins in response to DNA strand breaks in yeast. Cell 1999;97:621-33.
45. Gerhart-Hines Z, Rodgers JT, Bare O, Lerin C, Kim SH, Mostoslavsky R, et al. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. EMBO J 2007;26:1913-23.
46. Zhong L, Mostoslavsky R. Fine tuning our cellular factories: sirtuins in mitochondrial biology. Cell Metab 2011;13:621-6.
47. Scarpulla RC. Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. Biochim Biophys Acta 2011;1813: 1269-78.